If you follow wellness news, you have probably seen the headlines: the federal government has opened a door for compounding pharmacies to prepare several popular peptides. Our phones have noticed too.
So here is a plain-language rundown of what changed, what did not, and how Preston's Pharmacy is handling it.
What Actually Changed
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced an interim enforcement discretion policy for six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. In short, HHS said it does not intend to take enforcement action against state-licensed pharmacies that compound these peptides, as long as a specific set of conditions is met.
Those conditions matter. Each peptide is limited to certain dosage forms and routes of administration, the ingredients have to meet quality requirements, and the policy is explicitly temporary. It stays in place only until the FDA makes a final decision on each peptide through formal rulemaking.
In other words, this is a conditional, interim pathway. It is not a blanket green light.
Why We Are Not Racing to be First
All six peptides covered by the new policy are coming soon to Preston's, and our pharmacists have already formulated each one. But demand is high, some pharmacies will rush to market, and we think the right move is to finish our quality checks first.
The national compounding trade group, APC, made the same point to its members this month: being first should never come at the expense of ingredient quality. APC also noted that there is not yet much public evidence that peptide manufacturers are meeting the active pharmaceutical ingredient (API) standards the HHS policy requires.
That is the heart of it. A compounded medication is only as good as the raw ingredient that goes into it. Before we dispense any peptide under the new policy, every ingredient goes through the same process:
We validate the API manufacturer against the HHS policy requirements
We require a certificate of analysis (COA) for every lot
We send samples for our own independent, third-party testing to confirm identity, strength and purity
We confirm each preparation fits the dosage forms and routes the policy allows
If a supplier cannot show us all of that, we will not use it. That is a promise we make to every patient and every prescriber we work with.
Coming Soon: What We Are Preparing
These are not available yet. Once sourcing and testing are complete, all six peptides will be offered in the forms the HHS policy allows, please note some will be offered in formulations other than injectable:
KPV: topical and oral
Semax: intranasal
BPC-157, Epitalon, MOTS-c and TB-500: injectable
We are also evaluating an oral form of BPC-157. Oral peptides are tricky because the body can break them down before they are absorbed, and HHS itself describes oral absorption of peptides as difficult and complex. We will only offer an oral version if we are confident it is safe and adequately supported.
Our responsibility does not end when a prescription leaves the counter. As the policy requires, we will report serious adverse events connected to these products. If you notice any reaction, please tell your provider and let us know right away.
Federal Rules Are Only Half the Picture
Here is something many people miss: a federal policy does not automatically override state rules. Every pharmacy also answers to its state board of pharmacy, and states are now deciding how to respond.
Some states, such as Utah, have aligned with the federal approach. Others, including Arizona, are still reviewing their position. APC has raised concerns that a patchwork of different state rules could limit patient access even where federal policy allows it.
Preston's is licensed in Virginia, so Virginia Board of Pharmacy requirements apply to everything we do. We are watching the Board's position closely and will only move forward when we are confident we are fully compliant at both the federal and state level.
A Word of Caution on "American-Made" Claims
The FDA also recently warned about misleading marketing that labels certain GLP-1 weight loss products as "American-made" when their active ingredients actually came from overseas. It is a good reminder for patients: ask where the ingredients in your medication come from, not just where the final product was packaged. A reputable pharmacy should be able to answer that question.
What This Means for You
If you are a patient: Compounded peptides still require a prescription from a licensed provider. Talk with your provider first about whether a peptide is appropriate for you. Be wary of any source selling "research use only" peptides online. Those products are not made for people and carry real safety risks.
If you are a provider: We are happy to walk you through the dosage forms we are preparing, our sourcing and testing process, and our launch timeline for each of the six peptides. We will share updates as sourcing and state guidance become clear.
Questions? Email Us Before You Call
The fastest way to reach our team about peptides, pricing or provider referrals is by email at wellness@prestonspharmacy.com. Include your name, your provider's name and the medication you are asking about, and a pharmacist will get back to you.
We would rather get this right than get it first. Your health deserves nothing less.
